Apyx Medical reports preliminary Q4 revenue up ~34% YoY; Surgical Aesthetics up 38%

Apyx Medical Corp

Total Q4 revenue expected $19.0-19.2M, up ~34% YoY; FY revenue $52.7-52.9M, up ~10%.
Surgical Aesthetics Q4 revenue $16.6-16.8M (+38% YoY); U.S. Surgical Aesthetics up ~51% on AYON launch.
OEM Q4 revenue $2.4M (+13% YoY); FY OEM revenue $7.5M (-21% YoY).
CEO cites AYON momentum and GLP-1-driven demand for loose skin procedures.
Full financial results to be reported in March 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.